Bone sporotrichosis: 41 cases from a reference hospital in Rio de Janeiro, Brazil
Authors:
- Vanessa RamosVRVanessa Ramos
- Antonio C. F. Do ValleAVAntonio C. F. Do Valle
- Priscila M. de MacedoPriscila M. de Macedo
- Rodrigo Almeida-PaesRARodrigo Almeida-Paes
- Manoel M. E. OliveiraManoel M. E. Oliveira
- Rosely M. Zancopé-OliveiraRZRosely M. Zancopé-Oliveira
- Luciana G. P. BrandãoLBLuciana G. P. Brandão
- Marcel S. B. QuintanaMQMarcel S. B. Quintana
- Maria Clara Gutierrez-GalhardoMGMaria Clara Gutierrez-Galhardo
- Dayvison F. S. FreitasDFDayvison F. S. Freitas
Open Access
- 17 March 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (3) , e0009250
Abstract
Background: Bone sporotrichosis is rare. The metropolitan region of Rio de Janeiro is hyperendemic for zoonotic sporotrichosis and the bone presentations are increasing. Methods: We studied a retrospective cohort of 41 cases of bone sporotrichosis, diagnosed from 1999–2016. The inclusion criteria was fungal culture isolation from any clinical specimen associated to bone involvement (radiography and/or computed tomography) compatible with fungal osteomyelitis or histopathological findings of bone material compatible with sporotrichosis. Molecular identification was performed when possible. Results: Male patients represented 58.5% of the cases, with a cohort median age of 43 years. Immunosuppressive conditions were present in 68.3% of the patients, mostly HIV coinfection (51.2%). Multifocal bone involvement (more than one anatomical segment) was diagnosed in 61% of the patients, while 39% presented unifocal involvement. The bones of the hands were the most affected (58.5%), followed by the feet (41.5%) and tibia (26.8%). Multifocal group was characterized by a higher proportion of males (p = 0.0045) with immunosuppressive conditions (p = 0.0014). Amphotericin B followed by oral itraconazole was the main treatment, with a median time of 16.7 months (1.5 to 99.2 months), and cure of 53.7% of the patients (84.6% of immunocompetent and 39.3% of immunocompromised patients). Sequelae occurred in 12.2% of the patients—amputations (7.3%) and ankylosis (4.9%), while 22% died in the course of the disease. Sporothrix brasiliensis was the causative agent in all the 9 (22%) performed cases. Conclusions: Bone sporotrichosis is a chronic, challenging condition with prolonged treatment, often with poor results and sequelae.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (302796/2017-7)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (JCNE E-26/203.301/2017)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/202.527/2019)
- INI-FIOCRUZ
- Coordination for the Improvement of Higher Education Personnel (Finance Code 001)
This publication has 30 references indexed in Scilit:
- Cutaneous Disseminated Sporotrichosis Complicated by OsteomyelitisActa Dermato-Venereologica, 2013
- Rapid Identification of Sporothrix Species by T3B FingerprintingJournal of Clinical Microbiology, 2012
- Sporothrix schenckii and SporotrichosisClinical Microbiology Reviews, 2011
- Comparison between two race/skin color classifications in relation to health-related outcomes in BrazilInternational Journal for Equity in Health, 2011
- Zoonotic Sporotrichosis in Rio de Janeiro, Brazil: A Protracted Epidemic yet to Be CurbedClinical Infectious Diseases, 2010
- Disseminated sporotrichosis as a manifestation of immune reconstitution inflammatory syndromeMycoses, 2010
- Sporothrix schenckii infection presented as monoarthritis: report of two cases and review of the literatureClinical Rheumatology, 2005
- Sporotrichosis in Peru: Description of an Area of HyperendemicityClinical Infectious Diseases, 2000
- Long-Term Follow-Up of Multifocal Osteoarticular Sporotrichosis Treated with ItraconazoleClinical Infectious Diseases, 1996
- Osseous sporotrichosisThe American Journal of Medicine, 1971